Improved treatment and shorter duration of DR-TB treatment
Since 2014, THINK has implemented phase IIIII clinical trials to bring forward the first three new TB drugs in 50 years, including Bedaquiline, Pretonamid and Delamanid. Moreover, THINK has conducted the clinical trials that led the WHO to revise the international guidelines for TB treatment accordingly, first in 2019 and again in 2022.
These include the STREAM trial supported by USAID and Janssen Pharmaceuticals, which reduced duration of MDR-TB treatment from 2-years to 9 months and removed the need for injectable medication. More recently, with support from MSF, THINK completed the TB-PRACTECAL trial, which has reduced the duration of treatment even further to 6-months, using an all-oral regimen.